Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen recep...
Q1 2026
May 8, 2026
FY 2025
Mar 25, 2026
Q4 2025
Q3 2025
Nov 12, 2025
Q2 2025
Aug 12, 2025